FindTrial
Sign In

GLS-010

DRUG6 trials

Sponsors

Guangzhou Gloria Biosciences Co., Ltd.

Conditions

Advanced Solid TumorsCervical CancerClassic Hodgkin's LymphomaClassical Hodgkin's LymphomaPersistent, Recurrent, or Metastatic Cervical CancerRecurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin LymphomaSolid Tumor

Phase 1

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
CompletedNCT03713905
Guangzhou Gloria Biosciences Co., Ltd.Advanced Solid Tumors
Start: 2017-07-01End: 2022-02-28Updated: 2023-04-10
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
RecruitingNCT05909436
Guangzhou Gloria Biosciences Co., Ltd.Solid Tumor
Start: 2022-10-31End: 2026-12-31Target: 107Updated: 2023-06-18

Phase 2

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
NCT03655483
Guangzhou Gloria Biosciences Co., Ltd.Classical Hodgkin's Lymphoma
Start: 2018-08-24End: 2022-04-11Target: 85Updated: 2020-06-11
Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
NCT03972722
Guangzhou Gloria Biosciences Co., Ltd.Cervical Cancer
Start: 2019-05-15End: 2023-05-15Target: 89Updated: 2019-06-05

Phase 3

GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)
NCT05518318
Guangzhou Gloria Biosciences Co., Ltd.Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Start: 2022-09-30End: 2025-06-30Target: 60Updated: 2022-08-26
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
RecruitingNCT05798819
Guangzhou Gloria Biosciences Co., Ltd.Persistent, Recurrent, or Metastatic Cervical Cancer
Start: 2023-04-20End: 2030-12-01Target: 424Updated: 2026-09-16

Related Papers

Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial.
2024-11-26
773 A phase I/II study to evaluate the safety, tolerability and preliminary efficacy of GLS-012 monotherapy and in combination with zimberelimab in patients with advanced melanoma (Triumph-01)
Regular and Young Investigator Award Abstracts2023-10-31
Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study
International Journal of Gynecological Cancer2023-10-2420 citations
79P Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study
Immuno-Oncology Technology2022-12-01
673 Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II study
Regular and Young Investigator Award Abstracts2022-11-012 citations
Survival outcome of patients with relapsed or refractory classical Hodgkin lymphoma who achieved remission during immune checkpoint inhibitors treatment.
Journal of Clinical Oncology2022-06-01
Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study.
2021-08-2731 citations
357 GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in chinese patients with recurrent/metastatic cervical cancer: results from a multicenter, open-label, single-arm phase II trial
Poster2020-11-017 citations
Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.
Journal of Clinical Oncology2020-05-201 citations
Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.
Journal of Clinical Oncology2020-05-20
GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin’s lymphoma: Preliminary result of a phase II clinical trial.
Journal of Clinical Oncology2019-05-204 citations